GlassScriptPhysician profile
Lynn E Leatherwood
NPI 1750342986
$10,017.38
in general payments reported to CMS, 2019-2025
48 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $822 · 2021: $1,786 · 2022: $1,628 · 2023: $1,594 · 2024: $1,595 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,653.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,818.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $864.82 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $844.70 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $714.81 | 2021-2025 | Freestyle Libre |
| Lilly USA, LLC | $646.26 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $565.58 | 2019-2025 | Evenity, Repatha, Prolia |
| Sumitomo Pharma America, INC. | $427.07 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $403.65 | 2019-2023 | Myrbetriq |
| Abbvie INC. | $374.99 | 2021-2025 | |
| Pfizer INC. | $366.15 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.11 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $206.60 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $194.96 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $181.07 | 2022-2025 | Rexulti, Nuedexta |
| Sanofi-Aventis U.S. LLC | $179.30 | 2019-2020 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Leatherwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.